Balyasny Asset Management L.P. and related reporting persons filed Amendment No. 5 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,196,420 shares of Lexeo Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the five reporting persons disclosed beneficial ownership of 8,196,420 shares of Lexeo Therapeutics common stock (CUSIP 52886X107).
  • Percent of class: The 8,196,420 shares represent approximately 9.99% of outstanding shares, based on 82,046,255 shares outstanding as of August 10, 2026.
  • Share composition: The reported amount consists of 3,987,787 shares held directly and 4,208,633 shares issuable upon exercise of 5,586,529 warrants, subject to a beneficial ownership limitation.
  • Beneficial ownership cap: The warrants include a blocker preventing exercise if doing so would cause the holder to exceed 9.99% beneficial ownership of outstanding shares.
  • Direct holders: Shares are held directly by Atlas Diversified Master Fund, Ltd. (2,852,642 shares) and Atlas Private Holdings (Cayman) Ltd. (5,343,778 shares, including warrant shares), with Balyasny Asset Management L.P. acting as investment manager.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.

Balyasny Asset Management Discloses Near-10% Position via Warrants and Direct Shares

According to the filing, five related reporting persons jointly submitted Amendment No. 5 to Schedule 13G covering their beneficial ownership in Lexeo Therapeutics, Inc.: Balyasny Asset Management L.P. ("BAM"), BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, a United States citizen. All five entities are organized under Delaware law, except Mr. Balyasny, who is a United States citizen. Their principal business address is listed as 444 West Lake Street, 50th Floor, Chicago, IL 60606.

The filing states that BAM serves as the investment manager of two direct holders: Atlas Diversified Master Fund, Ltd., which holds 2,852,642 shares, and Atlas Private Holdings (Cayman) Ltd., which holds 5,343,778 shares including 4,208,633 shares issuable from the exercise of warrants. The filing notes that each reporting person is deemed to have sole voting power and sole dispositive power over all 8,196,420 shares, with no shared voting or dispositive power reported. The percent of class figure of 9.99% is calculated based on 82,046,255 shares outstanding as of August 10, 2026, as reported in Lexeo Therapeutics' Form 10-Q filed with the SEC on August 12, 2026.

The filing further discloses that the 5,586,529 warrants are subject to a "Beneficial Ownership Limitation," described as a blocker "which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise." The corporate chain runs from Dmitry Balyasny as Managing Member of Dames GP LLC, which serves as General Partner of Balyasny Asset Management Holdings LP, which is the Sole Member of BAM GP LLC, which is the General Partner of BAM.

What Was Disclosed

Balyasny Asset Management L.P. and four affiliated entities filed an amended Schedule 13G reporting 8,196,420 shares, or approximately 9.99%, of Lexeo Therapeutics common stock, including shares issuable upon warrant exercise subject to a 9.99% ownership cap.